Evorel® How to prescribe

Evorel® range gives you the option to meet the needs for peri- and post-menopausal women choosing HRT and adopt an individualised approach*

Evorel Conti- Continuous combined therapy.(3.2mg estradiol / 11.2mg norethisterone acetate patches) Indicated for

  • HRT in post-menopausal women, more than 6-month post menopause. (18 month since last period)

Evorel 50- Oestrogen only therapy (3.2mg estradiol patches). Indicated for

  • HRT for oestrogen deficiency symptoms in peri and postmenopausal women.
  • Prevention of osteoporosis in post-menopause women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved.

When to use the Evorel® range **

*** Add progestogen approved for addition to oestrogen treatment

E.g. Oral norethisterone, 1mg/day or medroxyprogesterone acetate, 2.5mg/day

  • for at least 12-14 days every month/28 day cycle
  • cyclic or continuous sequential

Reference
* Theramex Data on file. UK.DOF.002026 July 2020
** Adapted from HRT-Guide. British Menopause Society Tool for clinicians
*** Post menopausal women more than 6 months postmenopause (or 18 months since last period).

Information placed on this digital platform is not intended as a substitute for consultation with your healthcare professional. Please consult your doctor or nurse for further information.

Provide Feedback
close slider

Create your own user feedback survey